SLN 140
Alternative Names: SLN-140Latest Information Update: 17 Jan 2023
At a glance
- Originator Silence Therapeutics
- Class Amino sugars; Antihaemorrhagics; Drug conjugates; Small interfering RNA
- Mechanism of Action Protein S inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haemophilia